Oct 29, 2024 08:02AM

Oct 29, 2024 08:00AM

Oct 22, 2024 08:11AM

Oct 22, 2024 08:00AM

Oct 3, 2024 08:00AM

Jul 31, 2024 08:00AM

Jul 29, 2024 08:12AM Grifols (GRFS) receives expanded XEMBIFY label in U.S., strengthening its Ig portfolio for patients

Jul 29, 2024 08:00AM

Jul 1, 2024 06:01AM

Jul 1, 2024 06:00AM

Jun 17, 2024 04:20AM

Dec 12, 2023 08:00AM

Jul 20, 2023 08:16AM

Jul 20, 2023 08:15AM Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

May 11, 2023 08:30AM

Mar 6, 2023 07:05AM

Mar 6, 2023 07:00AM

Nov 3, 2022 09:00AM

Feb 24, 2022 06:12AM

Feb 24, 2022 06:00AM

Nov 4, 2021 09:00AM Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

Oct 19, 2021 11:18AM

Jun 1, 2021 10:30AM

Apr 15, 2021 11:59AM

Mar 9, 2021 03:15AM

Oct 9, 2020 06:27AM

Oct 9, 2020 06:23AM

Aug 24, 2020 08:41AM Convalescent Plasma Stocks Surge as FDA Issue Emergency Use Authorization

Jul 28, 2020 10:44AM

Jul 28, 2020 10:41AM

Jul 9, 2020 08:21AM

Jul 9, 2020 08:19AM

Jun 11, 2020 04:03AM

May 7, 2020 09:00AM

Apr 28, 2020 09:00AM Grifols launches new 3-mL (900-IU) vial for high-potency HyperRAB® (rabies immune globulin [human])

Apr 20, 2020 09:00AM

Mar 25, 2020 05:25PM

Dec 12, 2019 09:24AM

Dec 6, 2019 03:43PM

Dec 6, 2019 03:42PM

Nov 7, 2019 10:00AM

Jul 4, 2019 11:51AM Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

Feb 7, 2019 12:33PM

Feb 7, 2019 12:31PM

Jan 23, 2019 07:36AM

Jan 23, 2019 07:30AM

Jan 8, 2019 07:39AM

Jan 8, 2019 07:37AM

Nov 1, 2018 08:00AM Grifols affirms commitment to patients during Alpha-1 Awareness Month

Oct 12, 2018 09:58AM

322,094 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All